Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Burlulipase
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Burlulipase is a Enzyme drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Exocrine Pancreatic Insufficiency.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
October 19, 2012
Lead Product(s) : Burlulipase
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ancrod
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase I/ Phase II
Sponsor : ClinSupport | MWI Medizinisches Wirtschaftsinstitut GmbH | ProjectPharm s.r.o. | LCR Leading Clinical Research | X-act Cologne Clinical Research GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
Details : Ancrod is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hearing Loss.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 18, 2012
Lead Product(s) : Ancrod
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I/ Phase II
Sponsor : ClinSupport | MWI Medizinisches Wirtschaftsinstitut GmbH | ProjectPharm s.r.o. | LCR Leading Clinical Research | X-act Cologne Clinical Research GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
